Agila: the next billion dollar Indian acquisition in the works?
This article was originally published in Scrip
Agila Specialties is perhaps the next big deal on the horizon in the Indian pharmaceutical industry despite the carefully worded denial by Strides Arcolab's top brass on plans to hawk the firm’s crown jewel and injectables arm.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.